Hiroki Akiba

Hiroki Akiba

Auto-generated profile, based on publicly available information

Hiroki Akiba

Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in ACS Nano
Verified
Journal Article
Closed access
JXJinbing Xie
Jinbing Xie
DCDaniel Gonzalez Carter
Daniel Gonzalez Carter
TTTheofilus A. Tockary
Theofilus A. Tockary
NNNoriko Nakamura
Noriko Nakamura
YXYonger Xue
Yonger Xue
Kazunori KataokaKazunori Kataoka
Kazunori Kataoka

31 March 2020 in eLife
Verified
Journal Article
Open access
DKDaiki Kato
Daiki Kato
TYTomonori Yaguchi
Tomonori Yaguchi
TITakashi Iwata
Takashi Iwata
YKYuki Katoh
Yuki Katoh
KMKenji Morii
Kenji Morii
YKYutaka Kawakami
Yutaka Kawakami
Current xenogeneic mouse models cannot evaluate on-target off-tumor adverse effect, hindering the development of chimeric antigen receptor (CAR) T cell therapies for solid tumors, due to limited human/mouse cross-reactivity of antibodies used in CAR and sever graft-versus-host disease induced by administered human T cells. We have evaluated safety and antitumor efficacy of CAR-T cells targeting glypican-1 (GPC1) overexpressed in various solid tumors. GPC1-specific human and murine CAR-T cells generated from our original anti-human/mouse GPC1 antibody showed strong antitumor effects in xenogeneic and syngeneic mouse models, respectively. Importantly, the murine CAR-T cells enhanced endogenous T cell responses against a non-GPC1 tumor antigen through the mechanism of antigen-spreading and showed synergistic antitumor effects with anti-PD-1 antibody without any adverse effects in syngeneic models. Our study shows the potential of GPC1 as a CAR-T cell target for solid tumors and the importance of syngeneic and xenogeneic models for evaluating their safety and efficacy.

7 May 2015 in The Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
HAHiroki Akiba
Hiroki Akiba
KTKouhei Tsumoto
Kouhei Tsumoto
Antibodies (immunoglobulins) bind specific molecules (i.e. antigens) with high affinity and specificity. In order to understand their mechanisms of recognition, interaction analysis based on thermodynamic and kinetic parameters, as well as structure determination is crucial. In this review, we focus on mutational analysis which gives information about the role of each amino acid residue in antibody–antigen interaction. Taking anti-hen egg lysozyme antibodies and several anti-small molecule antibodies, the energetic contribution of hot-spot and non-hot-spot residues is discussed in terms of thermodynamics. Here, thermodynamics of the contribution from aromatic, charged and hydrogen bond-forming amino acids are discussed, and their different characteristics have been elucidated. The information gives fundamental understanding of the antibody–antigen interaction. Furthermore, the consequences of antibody engineering are analysed from thermodynamic viewpoints: humanization to reduce immunogenicity and rational design to improve affinity. Amino acid residues outside hot-spots in the interface play important roles in these cases, and thus thermodynamic and kinetic parameters give much information about the antigen recognition. Thermodynamic analysis of mutant antibodies thus should lead to advanced strategies to design and select antibodies with high affinity.

29 October 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HAHiroki Akiba
Hiroki Akiba
HTHiroko Tamura
Hiroko Tamura
MKMasato Kiyoshi
Masato Kiyoshi
SYSaeko Yanaka
Saeko Yanaka
KSKenji Sugase
Kenji Sugase
KTKouhei Tsumoto
Kouhei Tsumoto
Single-domain antibodies (VHHs or nanobodies), developed from heavy chain-only antibodies of camelids, are gaining attention as next-generation therapeutic agents. Despite their small size, the high affinity and specificity displayed by VHHs for antigen molecules rival those of IgGs. How such small antibodies achieve that level of performance? Structural studies have revealed that VHHs tend to recognize concave surfaces of their antigens with high shape-complementarity. However, the energetic contribution of individual residues located at the binding interface has not been addressed in detail, obscuring the actual mechanism by which VHHs target the concave surfaces of proteins. Herein, we show that a VHH specific for hen egg lysozyme, D3-L11, not only displayed the characteristic binding of VHHs to a concave region of the surface of the antigen, but also exhibited a distribution of energetic hot-spots like those of IgGs and conventional protein-protein complexes. The highly preorganized and energetically compact interface of D3-L11 recognizes the concave epitope with high shape complementarity by the classical lock-and-key mechanism. Our results shed light on the fundamental basis by which a particular VHH accommodate to the concave surface of an antigens with high affinity in a specific manner, enriching the mechanistic landscape of VHHs.

23 April 2010 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
HAHiroki Akiba
Hiroki Akiba
JSJun Sumaoka
Jun Sumaoka
MKMakoto Komiyama
Makoto Komiyama

16 June 2017 in The Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
KYKyohei Yumura
Kyohei Yumura
HAHiroki Akiba
Hiroki Akiba
SNSatoru Nagatoishi
Satoru Nagatoishi
OKOsamu Kusano-Arai
Osamu Kusano-Arai
HIHiroko Iwanari
Hiroko Iwanari
KTKouhei Tsumoto
Kouhei Tsumoto
Bispecific antibody targeting of two different antigens is promising, but when fragment-based antibodies are used, homogeneous production is difficult. To overcome this difficulty, we developed a method using the SpyTag/SpyCatcher system in which a covalent bond is formed between the two polypeptides. Using this method, we constructed a bispecific antibody that simultaneously interacted with two different epitopes of roundabout homologue 1 (ROBO1), a membrane protein associated with cancer progression. A bispecific tetravalent antibody with an additional functional moiety was also constructed by using a dimeric biotin-binding protein. An interaction analysis of ROBO1-expressing cells and the recombinant antigen demonstrated the improved binding ability of the bispecific antibodies through spontaneous binding of the two antibody fragments to their respective epitopes. In addition, multivalency delayed dissociation, which is advantageous in therapy and diagnosis.